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http://dx.doi.org/10.1016/j.ccr.2013.04.008SUMMARYGlioblastoma multiforme (GBM) displays cellular hierarchies harboring a subpopulation of stem-like cells
(GSCs). Enhancer of Zeste Homolog 2 (EZH2), the lysine methyltransferase of Polycomb repressive complex
2, mediates transcriptional repression of prodifferentiation genes in both normal and neoplastic stem cells.
An oncogenic role of EZH2 as a transcriptional silencer is well established; however, additional functions of
EZH2 are incompletely understood. Here, we show that EZH2 binds to and methylates STAT3, leading to
enhanced STAT3 activity by increased tyrosine phosphorylation of STAT3. The EZH2-STAT3 interaction pref-
erentially occurs in GSCs relative to non-stem bulk tumor cells, and it requires a specific phosphorylation of
EZH2. Inhibition of EZH2 reverses the silencing of Polycomb target genes and diminishes STAT3 activity,
suggesting therapeutic strategies.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and most
lethal primary brain cancer (Louis et al., 2007). The current stan-
dard of care for patients with GBM provides only palliation with a
median survival of about 15 months (Furnari et al., 2007; Stupp
et al., 2005).
Cancer stem/propagating cells (CSCs) are functionally defined
by the enriched capacity to propagate tumors in vivo, and have
characteristics of normal stem cells such as self-renewal and dif-
ferentiation potential to establish cellular hierarchy and hetero-
geneity (Dirks, 2010; Reya et al., 2001). While some cancers
may not follow the CSC model, numerous studies support thatSignificance
Elucidation of the regulatory pathways operating in stem-like c
primary human tumors and may help lead to better therapies. W
silencing but also contributes to the activation of STAT3, a key
(pS21 EZH2) by AKT signaling facilitates STAT3 methylation b
histone methylation-independent EZH2-STAT3 signaling decre
these data suggest that the AKT-EZH2-STAT3 axis is a positive
promising therapeutic target for GBM.GBMs harbor a subpopulation of highly tumorigenic, stem-like
cells (GSCs) (Dirks, 2010; Hemmati et al., 2003; Singh et al.,
2004), and that GSCs are responsible for glioma propagation,
resistance to conventional therapy, and tumor recurrence (Bao
et al., 2006; Chen et al., 2012; Gilbert and Ross, 2009; Zhou
et al., 2009). Therefore, it may be crucial to identify the mecha-
nisms involved in GSC maintenance.
Polycomb group (PcG) proteins are important epigenetic reg-
ulators of embryonic development and cell fate decision (Mar-
gueron and Reinberg, 2011; Richly et al., 2011; Sparmann and
van Lohuizen, 2006). They execute transcriptional repression in
two multiprotein complexes named Polycomb repressive com-
plexes 1 and 2 (PRC1 and PRC2). Core components of PRC2ancer cells will be critical to understand the pathogenesis of
e demonstrate that EZH2 not only mediates transcriptional
GSC signaling node. Phosphorylation of EZH2 at serine 21
y EZH2 and enhances STAT3 activity. Selective blocking of
ases tumor growth in an orthotopic animal model. Together,
regulator of GSC self-renewal and tumor malignancy, and a
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EZH2-STAT3 Interaction in Glioblastoma Stem Cellsinclude EZH2 (enhancer of Zeste homolog 2), Suz12 (suppressor
of Zeste 12), and EED (embryonic ectoderm development) (Spar-
mann and van Lohuizen, 2006). EZH2 functions as a lysine
methyl transferase and EZH2-containing PRC2 catalyzes trime-
thylation of histone 3 at lysine 27 (H3K27me3) (Cao et al., 2002).
PRC1 in turn recognizes the H3K27me3 mark and maintains
gene silencing (Shao et al., 1999; Sparmann and van Lohuizen,
2006).
Many of the PRC2 target genes in embryonic and tissue-spe-
cific stem cells are lineage-committed prodifferentiation genes,
supporting Polycomb-mediated maintenance of stem cells
(Boyer et al., 2006; Lee et al., 2006b; Mikkelsen et al., 2007).
Several genome-wide integrative studies have revealed that a
significant subset of PRC2 target genes is repressed in various
tumors, some of which are further silenced by promoter hyper-
methylation, implying crucial roles of the Polycomb pathway in
cancer initiation and progression (Schlesinger et al., 2007; Vire´
et al., 2006; Widschwendter et al., 2007). In a wide range of
cancers including GBM, EZH2 is highly expressed and its
expression positively correlates with tumormalignancy and inva-
siveness (Crea et al., 2010; Kleer et al., 2003; Varambally et al.,
2002). We and others have previously shown that EZH2 is a
critical regulator for GSC maintenance and GBM propagation
(Abdouh et al., 2009; Lee et al., 2008; Suva` et al., 2009).
The reported roles of EZH2 have been attributed to its ability to
drive transcriptional repression via a repressive histone mark,
especially H3K27 trimethylation (Esteller, 2008; Morey and Helin,
2010; Simon and Kingston, 2009; Simon and Lange, 2008). How-
ever, emerging evidence suggests the presence of additional
downstream effectors of EZH2 signaling (Cha et al., 2005; He
et al., 2012; Lee et al., 2011; Wei et al., 2008; Xu et al., 2012).
Consistent with this hypothesis, recent studies reported that
EZH2 interacts with various transcription factors including
androgen receptor (AR), GATA4, and RORa (He et al., 2012;
Lee et al., 2012; Xu et al., 2012). A series of reports showed
that histone methyltransferases such as SET7/9 can regulate
signaling pathways through direct methylation of p53, NF-kB,
and STAT3 (Huang et al., 2006; Lu et al., 2010; Stark et al.,
2011; Yang et al., 2010), raising the possibility that EZH2 might
have such a property. Based on this background, we investi-
gated the histone methylation-independent role of EZH2 in
GSC self-renewal and GBM propagation.
RESULTS
EZH2 Interacts with STAT3 in GSCs
To identify proteins that interact with EZH2, we performed co-
immunoprecipitation (IP) experiments using an anti-EZH2 anti-
body and characterized proteins that coprecipitate with EZH2
by mass spectrometry (data not shown). GBM cells prospec-
tively enriched by the putative GSC enrichment markers
CD133 and/or CD15 (Singh et al., 2004; Son et al., 2009) were
isolated from surgical specimens of GBM patients or their deriv-
ative xenograft tumors and functionally validated in assays of
self-renewal and tumor propagation (Joo et al., 2013; Lee
et al., 2008; Pastrana et al., 2011; Pollard et al., 2009). We found
that EZH2 coprecipitated with STAT3 in protein lysates isolated
from CD133 and/or CD15-enriched GSCs (Figure 1A). Co-IP
experiments using an anti-STAT3 antibody in the same lysates840 Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc.revealed that STAT3 coprecipitated with EZH2 as well as
SUZ12 and EED, other core components of PRC2, suggesting
that STAT3 and PRC2 may interact in GSCs (Figure 1B).
Because EZH2 is implicated in the maintenance of normal
and neoplastic stem cells, we assessed whether the EZH2-
STAT3 interaction is affected by the differentiation states of
these cells. The addition of serum or the removal of epidermal
growth factor (EGF) and fibroblast growth factor 2 (FGF2) in
culture media decreased expression of stem-cell-associated
markers such as SOX2 and concurrently increased an astroglial
marker expression (e.g., GFAP), consistent with a ‘‘differenti-
ated’’ phenotype (Galli et al., 2004; Lee et al., 2006a; Piccirillo
et al., 2006; Zheng et al., 2010). We determined the relative
abundance of the EZH2-STAT3 complex in two pairs of
GSCs and their differentiated progenies by co-IP assays. An
association between EZH2 and STAT3 was prominent in
GSCs, but lost in the cells cultured in the presence of serum
or the absence of growth factors (Figure 1C; Figure S1 available
online), providing an initial link between the EZH2-STAT3 inter-
action and GSC maintenance. Because GSCs share many
characteristics with normal human neural stem/progenitor cells
(NPCs), we assessed whether the EZH2-STAT3 association is
present in NPCs derived from fetal brain tissues. Similar to
GSCs, EZH2 and STAT3 were co-immunoprecipitated in
NPCs but not in differentiated cells (Figure 1C). Collectively,
these data demonstrate an interaction between EZH2 and
STAT3 in GSCs.
We performed additional co-IP experiments to determine the
EZH2-STAT3 interaction in GSC-derived GBM xenografts or
other glioma cell lines. U87 and U251 are two most widely
used, established glioma cell lines. EZH2 and STAT3 proteins
were expressed in these cells at comparable levels. While the
EZH2-STAT3 coprecipitation was abundant in GSCs and GBM
xenografts, it was barely detectable in lysates isolated from
U87 and U251 (Figure 1D).
EZH2 Targeting Decreases STAT3 Activation in GSCs
Because an association between EZH2 and STAT3 is abundant
in GSCs, and STAT3 is a key signaling node in GSCs (Cao et al.,
2010; Sherry et al., 2009; Yang et al., 2012), we hypothesized
that EZH2 may positively regulate STAT3 signaling in GSCs.
To investigate the role of EZH2 in STAT3 activation, we targeted
EZH2 expression by lentiviral-mediated short hairpin RNA
(shRNA) directed against EZH2 (shEZH2) and measured
STAT3 activation in GSCs (Figure 2A). Some GSCs appear
to have a constitutively active STAT3 signaling, evidenced
by a high basal level of tyrosine phosphorylated STAT3 at the
705 residue (pY-STAT3) (Cao et al., 2010). As expected, EZH2
knockdown greatly decreased global levels of H3K27
trimethylation in GSCs. EZH2 knockdown in two different
GSCs also reduced the levels of pY-STAT3 to 30% of those
in nontargeting shRNA-transduced GSCs (Figures 2A and 2B).
We complemented these findings using a prototype EZH2 inhib-
itor (3-deazaneplanocin A, DZNep) (Tan et al., 2007) and a highly
selective EZH2 inhibitor GSK126 (McCabe et al., 2012). pY-
STAT3 in GSCs was rapidly decreased by treatment with either
DZNep or GSK126 (Figure 2C). In contrast, the levels of phos-
phorylated AKT and ERK in GSCs were not changed within
4 hr of drug treatment (Figure 2C).
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Figure 1. EZH2 Protein Interacts with STAT3
in GSCs
(A and B) Co-immunoprecipitation (Co-IP) of EZH2
and STAT3 in GSCs (827 and 387). IgG represents a
control antibody used for IPs. For IP-immunoblot-
ting data, antibodies used for IP and western blot-
ting were labeled as red and blue, respectively. Two
hundred micrograms of lysates were used for each
IP reaction and total lysates (20 mg) were used as
input controls.
(C) Co-IP and immunoblot analysis of EZH2 and
STAT3 in GSCs and NPCs versus differentiated
progenies. Differentiation was induced by culturing
these cells in serum (10%)-containing media for
3 days. The EZH2-STAT3 complex was analyzed by
co-IP, followed by immunoblot analysis. Protein
levels of EZH2, SOX2 (a GSC-specific transcription
factor), and GFAP (an astroglial differentiation
marker) were examined. b-actin was used as a
loading control.
(D) Co-IP and immunoblots of the EZH2-STAT3
complexes in various cells. A 293T cell line (derived
from human embryonic kidney cells) was used as a
reference.
See also Figure S1.
Cancer Cell
EZH2-STAT3 Interaction in Glioblastoma Stem CellsBecause STAT3 functions as a transcription factor, we deter-
mined the functional effects of decreased STAT3 activity in
GSCs after EZH2 inhibition. We performed real-time RT-PCR
analysis to measure mRNA expression of validated STAT3 tran-
scriptional target genes including STAT3, SOCS3, and c-MYC
(Figure 2D) in EZH2-inhibited cells (Frank, 2007). Messenger
RNA levels of these genes were significantly decreased in
GSCs treated with DZNep or EZH2 knockdown cells compared
to the control (Figure 2D and data not shown). In addition, we
determined STAT3 transcriptional activity by STAT3 responsive
promoter reporter assays in which a luciferase reporter was
driven by a STAT3 DNA-binding sequence-containing promoter.
STAT3 transcriptional activity was substantially lower in cells
treated with DZNep or EZH2 knockdown cells than in the con-
trols (Figure 2E and data not shown). Together, these data sup-
port that EZH2 may directly regulate STAT3 activity in GSCs.
STAT3 Is Methylated by EZH2 in GSCs
BecauseEZH2methylates specific lysine residuesof histonepro-
teins andEZH2 interactswith STAT3,we hypothesized that EZH2
methylates STAT3. By immnuoprecipitation with an anti-STAT3
antibody followed by immunoblotting using a pan-methyl lysine
antibody,we found that STAT3 ismethylated inGSCs (Figure 3A).
To interrogate the role of EZH2 inSTAT3methylation,we targeted
EZH2 genetically (shRNA-mediated knockdown) or pharmaco-
logically (with DZNep), and then assessed the methylation statusCancer Cell 23, 839–of STAT3 protein in GSCs. In both cases,
STAT3 methylation was markedly de-
creased (Figures 3A and 3B). To determine
whether a methyltransferase activity of
EZH2 is required for STAT3 methylation,
we overexpressed a methyltransferase-
inactive EZH2 H689A mutant (Kuzmichev
et al., 2002) in GSCs via lentiviral transduc-tion and assessed the level of STAT3 methylation (Figure 3C).
Ectopic expression of EZH2H689Amutant decreasedH3K27 tri-
methylation and reversed transcriptional repression of Dickkopf-
1 (Dkk1), aWntantagonist andPolycomb targetgene (Go¨tzeet al.,
2010; Hussain et al., 2009), suggesting that this mutant functions
as a dominant-negative form (Figures 3C and 3D). Compared to
the GFP-transduced cells or the wild-type EZH2-transduced
cells, EZH2 H689A mutant-transduced cells showed decreased
STAT3 methylation (Figure 3C). Collectively, these data support
that STAT3 methylation in GSCs is mediated by EZH2.
EZH2 Inhibition Decreases STAT3 Methylation and
Activity in GBM Xenografts
Because EZH2-STAT3 interaction is prominent in GSCs in vitro,
we determined STAT3 methylation status in GBM xenografts.
Protein lysates of GBM xenograft tumors derived from four
different GSCs were interrogated by reciprocal co-IP experi-
ments using anti-STAT3 and methylated lysine-specific anti-
bodies. Methylated STAT3 was present in lysates from all tumors
tested (Figure 3E). Next, we determined whether EZH2 inhibition
could affect STAT3 methylation and STAT3 activity in GBM
in vivo by using two complementary approaches. First, we
implanted GSCs expressing either EZH2 shRNA or control
shRNA into the brains of immunocompromised mice. Second,
we generated GSC-derived xenograft tumors and treated the
animals with DZNep after tumors were established. EZH2852, June 10, 2013 ª2013 Elsevier Inc. 841
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Figure 2. EZH2 Targeting Decreases STAT3
Activation in GSCs
(A) Immunoblots of EZH2, H3K27me3, pY-STAT3
(Y705) and total STAT3 in GSCs transduced with
shEZH2-I, shEZH2-II, or nontargeting (NT) control
shRNA.
(B) Quantification of protein intensities in immu-
noblots including the one shown in (A) was per-
formed by densitometry.
(C) Immunoblots of pY-STAT3 and total STAT3 in
GSCs treated with EZH2 inhibitors DZNep (2 mM)
or GSK-126 (2 mM) for the indicated times (0 hr to
4 hr). Representative blots using 827 cells were
shown.
(D) Semiquantitative real-time RT-PCR analysis to
determine mRNA expression of STAT3 target
genes in GSCs (827 and 387) treated with DZNep
for 1 day. Expression levels of these genes were
normalized and compared to those of the un-
treated control cells. Data are means ± SD (n = 3).
(E) Determination of STAT3 transcription activity by
STAT3-responsive luciferase reporter assays.
Luciferase activities in GSCs treated with DZNep
were compared to those of the untreated control.
Cells treated with cucurbitacin (a STAT3 inhibitor)
were used as a positive control. Error bar repre-
sents SD. *p < 0.01.
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EZH2-STAT3 Interaction in Glioblastoma Stem Cellsknockdown (Figures 3F and 3G) or DZNep treatment (Figures 3H
and 3I) decreased the growth of xenograft tumors. Tumors ob-
tained from both experiments were dissected and processed
for western blot analysis and co-IP experiments. Compared to
the controls, tumors treated with DZNep or tumors expressing
EZH2 shRNA showed low levels of STAT3 methylation and pY-
STAT3 (Figures 3F–3J). Furthermore, immunohistochemcial
analyses on tumor sections showed the decreased number of
pY-STAT3 positive cells in tumors treatedwith DZNep compared
to the control (Figure 3K). Taken together, these data demon-
strate that targeting EZH2 effectively inhibits H3K27methylation,
STAT3 methylation, and STAT3 activation in GBM xenografts.
STAT3 Methylation Positively Regulates STAT3 Activity
in GSCs
To analyze the methylation status of STAT3 protein, we overex-
pressed Flag-tagged STAT3 (Flag-STAT3) in GSCs and gener-842 Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc.ated xenograft tumors using these cells.
The tagged STAT3 was phosphorylated
normally in response to EGF and inter-
leukin-6 (IL-6), potent inducers for pY-
STAT3 (Zhong et al., 1994). Flag-STAT3
protein was purified from GSC-derived
xenograft tumors and analyzed by mass
spectrometry (MS). A mass shift of +42
was observed for a STAT3 peptide,
consistent with trimethyl modifications
(Figure S2A). The previously reported
lysine 140 methylation of STAT3 was not
detected in these tumors with MS anal-
ysis (Yang et al., 2010) (data not shown).
Because the methylation was in a peptide
that includes residues 178 to 197, andtandem MS analysis localized the site to lysine 180 (K180) (Fig-
ure S2A), we generated lentiviruses expressing STAT3 mutants
in which a K180 residue of STAT3 protein was replaced by
alanine (A) or arginine (R). We overexpressed these STAT3
mutants in GSCs and performed co-IP experiments to assess
the methylation status of these proteins and the interaction
with EZH2 (Figure 4). While exogenous wild-type STAT3 was
methylated, both K180A and K180R mutants showed little or
no methylation (Figure 4A). Similarly, STAT3 K180 mutants
were unable to immunoprecipitate with EZH2 in contrast to the
wild-type STAT3 (Figure 4A). These data support K180 of
STAT3 as a key residue required for the EZH2-STAT3 interaction
and EZH2-mediated STAT3 methylation.
Because pY-STAT3 is an important indicator of STAT3 activ-
ity, we performed IP experiments to determine the phosphoryla-
tion status of exogenous STAT3 proteins. While wild-type STAT3
was phosphorylated at tyrosine 705, both K180A and K180R
A  B  
IP : Methyl K 
WB : STAT3
IP : STAT3 
WB : Methyl K
EZH2 
-Actin
IP : STAT3 
WB : STAT3
NT shEZH2 NT shEZH2 
827 387 
IP 
Total  
lysates 
827 387 
DZNep      -       +           -         + 
IP : STAT3 
WB : Methyl K
IP : STAT3 
WB : STAT3
IP : Methyl K 
WB : STAT3
EZH2 
-Actin
IP 
Total  
lysates 
C  
827 387 633 727 
Input  IgG IP Input  IgG IP Input  IgG IP Input  IgG IP 
IP : Methyl K 
WB : STAT3 
IP : STAT3 
WB : STAT3 
IP : STAT3 
WB : Methyl K 
D  
5 15  17 20 24 
0
200
400
600
800
Days
M
ea
n
T
u
m
o
r
M
as
s
(m
m
3 ) Vehicle (Saline)
DZNep (1 mg/kg)
** 
C
on
t 
D
ZN
ep
 
pY-STAT3 Merge 
IP : STAT3 
WB : Methyl K 
IP : STAT3 
WB : STAT3 
IP : Methyl K 
WB : STAT3 
Cont  DZNep 
827 tumor 
EZH2 
H689A 
EZH2 
WT GFP 
IP: Methyl K 
WB: STAT3 
Endo. 
Exo. EZH2 
-Actin
H3K27me3 
HistoneH3 
387 
GSC-derived GBM xenografts 
E  
NT   shEZH2 
EZH2 
pY-STAT3 
H3K27me3 
-Actin 
STAT3 
F G 
EZH2 
H3K27me3 
pY-STAT3 
Histone H3 
STAT3 
-Actin 
Cont  DZNep I H 
211 
827 
J 
K 
827 derived xenograft 
Figure 3. EZH2 Methylates STAT3 Protein
in GSCs
(A and B) Co-IP and immunoblots of the methyl-
ated STAT3 in GSCs. Either EZH2 knockdown (A)
or treatment with DZNep (B) decreased methyl-
ated STAT3 in GSCs. Methyl K represents an
antibody recognizing the methylated lysine.
(C) Co-IP and immunoblots of the methylated
STAT3 in GSCs that expressGFP, wild-type EZH2,
and EZH2 H689A. Arrows indicate protein bands
of endogenous EZH2 (endo) and exogenous EZH2
transgenes (exo).
(D) Expression levels of DKK1, a PRC2 target
gene, in GSCs expressing EZH2 transgenes were
determined by real-time RT-PCR analysis. Data
are means ± SD (n = 3). *p < 0.01.
(E) IP and immunoblots of methylated STAT3 in
various GSC-derived GBM tumors.
(F) Kaplan-Meier survival curves of mice ortho-
topically implanted with 211 GSCs transduced
with either control or EZH2 shRNA expressing
lentivirus (n = 7). p < 0.01.
(G) Immunoblots of pY-STAT3 and H3K27me3 in
xenograft tumors (F). Human tumor cells were
harvested 3 months after intracranial implantation
and processed for immunoblot analysis.
(H–J) Measurement of subcutaneous xenograft
tumor size after treatment with DZNep. Error bar
represents SD (n = 5). **p < 0.01. GSC-derived
xenograft tumors were treated with DZNep
(1 mg/kg body weight twice a week via intraperi-
toneal injection) for 2 weeks, harvested, and pro-
cessed for immunoblots and co-IP analysis (I) and
(J) and IF staining (K).
(K) IF staining of pY-STAT3 (green) on the frozen
sections of GBM xenografts treated with vehicle or
DZNep. Nuclei were stained with DAPI. Bar rep-
resents 10 microns.
Cancer Cell
EZH2-STAT3 Interaction in Glioblastoma Stem Cellsmutants showed little or no phosphorylation (Figure 4A). To
further investigate the effects of K180 mutation on STAT3
function, we overexpressed wild-type STAT3 and STAT3 K180
mutants in PC3, a STAT3 null prostate cancer cell line. After
treatment with IL-6, activating tyrosine phosphorylation of
STAT3 was evident in the wild-type STAT3-PC3 cells but not in
STAT3 K180 mutant-PC3 cells (Figures S2B and S2C). Consis-
tent with this, overexpression of K180 STAT3 mutant in PC3
failed to increase STAT3 transcriptional activity responding to
IL-6. To interrogate the role of these STAT3 mutants in GSCs,
we performed similar experiments in GSCs in which endogenous
STAT3 signaling is active. Luciferase reporter assays to monitor
STAT3 transcriptional activation revealed that STAT3 K180
mutant-expressing cells were impaired in the ability to activate
STAT3, in contrast to the wild-type STAT3-expressing GSCs
(Figure 4B). Unlike wild-type STAT3, overexpression of STAT3
K180A in GSCs did not increase transcription of STAT3 target
genes, such as SOCS3 and c-MYC (Figure 4C). Because nuclearCancer Cell 23, 839–8accumulation of pY-STAT3 is another in-
dicator of STAT3 activation, we assessed
the levels of nuclear pY-STAT3 in STAT3
mutant-expressing GSCs. pY-STAT3
was highly accumulated after IL-6 chal-lenge in empty vector control GSCs or the wild-type STAT3-ex-
pressing GSCs but not in STAT3 K180 mutant-expressing cells
(Figure 4D and data not shown). In GSCs, STAT3 signaling pro-
motes activation of stem cell-associated transcriptional factors
including Olig2, Sox2, and Nanog (Guryanova et al., 2011). Over-
expression of wild-type STAT3 but not STAT3 K180A mutant
induced transcription of these genes (Figure 4E). We then
assessed the effect of STAT3 mutants on the growth of GSCs.
Compared to the wild-type STAT3-expressing cells, STAT3
K180 mutant-expressing cells were less proliferative (Figures
4F–4H). Clonogenic growth as a form of sphere is an in vitro
indicator of GSC self-renewal. To determine the role of STAT3
K180 mutants on clonogenic growth of GSCs, we performed
neurosphere formation limiting dilution assays. Tumor cells
were plated into 96-well plates with various seeding densities
and allowed to grow. Compared to the empty vector control
and the wild-type STAT3, ectopic expression of STAT3 K180
mutants reduced the efficiency of sphere formation (Figure 4I).52, June 10, 2013 ª2013 Elsevier Inc. 843
Figure 4. Effects of STAT3 Methylation on STAT3 Activity and GSC Self-Renewal
(A) Co-IP analyses of methylated STAT3, pY-STAT3 and the EZH2-STAT3 complex in 131 GSCs expressing STAT3 K180 mutants. V5 is a protein tag fused with
STAT3. Methyl K denotes an antibody recognizing either di- or trimethylated lysine.
(B) STAT3 transcriptional activity in response to IL-6 in 131 GSCs expressing the empty vector control, wild-type STAT3, or the STAT3 K180 mutants.
*p < 0.01.
(C) Real-time RT-PCR analysis to determine mRNA levels of SOCS3 and c-MYC in GSCs (827 and 131) expressing either wild-type or STAT3 K180A mutant.
Messenger RNA levels of SOCS3 and c-MYC in STAT3 K180 expressing cells were compared to those in wild-type STAT3 expressing cells (set to 1). Data are
means ± SD (n = 3). *p < 0.01.
(D) IF staining of pY-STAT3 (green) on GSCs expressing the wild-type STAT3 and STAT3 K180 mutants in response to IL-6 (50ng/ml). V5 (red) was used to stain
exogenous STAT3 and DAPI (blue) was used to stain nuclei.
(E) Real-time RT-PCR analysis to determine mRNA expression of stem cell associated transcription factors (OLIG2, SOX2, and NANOG) in GSCs (827 and 131)
expressing STAT3 mutants. Data are means ± SD (n = 3). *p < 0.01.
(F–I) Effects of STAT3 K180 mutant overexpression on proliferation and clonogenic growth of GSCs. 50-ethynyl-20-deoxyuridine (EdU)-positive cells (stained
green) were counted in three random fields and plotted (in F and G). *p < 0.01. Cell counts of STAT3 mutant-expressing GSCs after 6 days of culture (H) and
limiting dilution assay results (I) were shown. Error bars represent SD. Bars (in D and F) represent 10 microns. See also Figure S2.
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Figure 5. AKT Signaling Is Essential for the
EZH2-STAT3 Interaction in GSCs and AKT
Inhibition Decreases STAT3 Activity in GBM
Xenografts
(A) Immunoblot analysis of AKT, pS473 AKT,
EZH2, pS21 EZH2, and trimethylated H3K27 in
GSCs treated with a PI3K/AKT pathway inhibitor
LY294002.
(B and C) Co-IP analysis of methylated STAT3 and
the EZH2-STAT3 complex in GSCs treated with
LY294002 for 1 day.
(D) Tumor growth of 827 GSC-derived xenografts
treated with an AKT inhibitor perifosine (30 mg/kg
body weight). Twenty-three days after tumor
implantation in mice, perifosine was administered
by intraperitoneal injection (daily for 5 days). Error
bars represent SD. Five mice per group, *p < 0.01.
(E) Immunoblot analysis of pY-STAT3, EZH2, AKT,
and trimethylated H3K27 in lysates from xenograft
tumors in (D).
(F) Co-IP analysis of methylated STAT3 in GBM
xenograft tumors treated with perifosine.
(G) IF staining of pS21 EZH2 and pY-STAT3 on the
frozen sections of GBM xenografts treated with
vehicle or perifosine. Nuclei were stained with
DAPI. Bar represents 10 microns.
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EZH2 methylates STAT3 at K180 and this methylation enhances
STAT3 activation and promotes clonogenic growth of GSCs.
AKT Signaling Is Essential for the EZH2-STAT3
Interaction in GSCs
Because our data indicate that the EZH2-STAT3 interaction
leads to STAT3 activation, we investigated a potential upstream
effector(s) to facilitate this interaction. An initial clue came from a
previous study in which the authors reported that EZH2 is phos-
phorylated at serine residue 21 (pS21 EZH2) by AKT (Cha et al.,
2005). Cha et al. showed that phosphorylation of EZH2 at S21
significantly decreased H3K27 trimethylation leading to the
derepression of PRC2 target genes (Cha et al., 2005). However,
breast cancer cells overexpressing EZH2S21D (phosphorylation
mimetic mutant of pS21 EZH2) showed increased proliferation
and invasiveness. H3K27 trimethylation and PRC2-mediated
transcriptional repression are generally associated with tumor
malignancy, thus an oncogenic role of EZH2 phosphorylation
appears to be counterintuitive. A potential explanation for this
discrepancy is that S21 phosphorylation of EZH2 may exert pro-Cancer Cell 23, 839–tumorigenic functions in H3K27 in a trime-
thylation-independent manner, as sug-
gested in a recent report (Xu et al., 2012).
Because EZH2 interacts with and
methylates STAT3, we hypothesized that
STAT3 is one such molecule to exert pro-
tumorigenic functions in GSCs. PI3K/AKT
signaling is highly active in about 90% of
GBM specimens (Fan et al., 2006; Fan
and Weiss, 2010; Cancer Genome Atlas
Research Network, 2008; Verhaak et al.,
2010) and all of GSCs we tested have ahigh level of activating phosphorylation of AKT (Figure 2C and
data not shown). In agreement with the previous reports (Cha
et al., 2005; Costa et al., 2010), treatment with LY294002
(a PI3K-AKT inhibitor) or perifosine (an AKT inhibitor) blocked
S21 phosphorylation of EZH2 but increased global levels of
H3K27 trimethylation in GSCs (Figure 5A). In GSCs treated
with these inhibitors, levels of EZH2-STAT3 complexes and
methylated STAT3 were markedly reduced compared to con-
trols (Figures 5B and 5C). Overexpression of a dominant-nega-
tive AKT in GSCs showed similar results (data not shown).
Together, these data suggest that AKT signaling is required for
the EZH2-STAT3 interaction and STAT3 methylation in GSCs.
AKT Inhibition Decreases Methylation and Activation of
STAT3 in GBM Xenografts
To address the relevance of the above findings in vivo, we estab-
lished GSC-derived xenograft tumors and evaluated the effects
of AKT inhibition on STAT3 activity and tumor growth (Figure 5).
Animals treated with perifosine for 5 days displayed reduced tu-
mor size relative to those treated with vehicle control (Figure 5D).
One day after the final injection of perifosine, we dissected852, June 10, 2013 ª2013 Elsevier Inc. 845
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Figure 6. Phosphorylation of EZH2 at Serine
21 Is Critical for STAT3 Methylation and
STAT3 Activity in GSCs
(A) Co-IP and Immunoblot analysis of pS21 EZH2
and methylated STAT3.
(B) Immunoblot analysis of pS21 EZH2 in GSC-
enriched or GSC-depleted GBM cells (CD133+
or  and CD15+ or ).
(C) Co-IP and immunoblot analyses of methylated
STAT3 in GSCs transduced with various EZH2
mutants. EZH2 transgenes were detected by
Flag tag.
(D) Quantification of methylated STAT3 shown in
(C). Protein amounts were estimated by densi-
tometry of immunoblots. Error bars represent SD.
*p < 0.01.
(E and F) Real-time RT-PCR analysis to determine
mRNA expression of STAT3 and SOCS3 in 131
GSCs expressing various EZH2 mutants. Data are
means ± SD (n = 3). *p < 0.01.
(G) Determination of STAT3 transcription activity
by reporter promoter assays. Luciferase activity in
GSCs expressing various EZH2 constructs was
compared to that of the GFP-expressing control
cells. Error bars represent SD. *p < 0.01.
(H) Effects of ectopic expression of various EZH2
constructs on GSC tumorsphere formation. GSC
cells (131) transduced with lentivirus expressing
various EZH2 transgenes were cultured for limiting
dilution assays. Frequency of stem-like clonogenic
cells was determined by aweb-based tool ‘‘ELDA’’
(extreme limiting dilution analysis, available on
http://bioinf.wehi.edu.au/software/elda/) and rep-
resented as a box plot. Boxes indicate the upper
and lower confidence intervals, and the lines
denote the estimated values. *p < 0.01.
See also Figure S3.
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Compared to the control, tumors treated with perifosine showed
low levels of phosphorylated AKT and EZH2 phosphorylation
(Figure 5E). Consistent with in vitro results, AKT inhibition in vivo
decreased STAT3 methylation and pY-STAT3, but increased
global levels of H3K27 trimethylation (Figures 5E and 5F). Immu-
nofluorescence analyses on tumor sections further confirmed
that perifosine treatment decreased pS21 EZH2 and nuclear
PY-STAT3 (Figure 5G). Together, these data suggest that AKT
regulates STAT3 signaling in part via EZH2 phosphorylation
and STAT3 methylation.
GSCs Have a High Level of EZH2 Phosphorylation at
Serine 21
Because phosphorylation of EZH2 at S21 appears to be an
important signal node between AKT signaling and STAT3
methylation in GSCs, we determined the levels of pS21 EZH2
and STAT3 methylation in various GBM cells. Immunoblot anal-846 Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc.ysis showed that pS21 EZH2 is highly ex-
pressed in GSCs but not in U87 and U251
glioma cell lines (Figure 6A). Similarly,
STAT3 methylation was abundant in
GSCs but much lower in glioma cell lines
(Figure 6A). This trend is entirely consis-tent with the level of the EZH2-STAT3 complex in these cells (Fig-
ure 1D). To further examine preferential expression of pS21
EZH2 in GSCs, we used four additional GBM cells with prospec-
tive sorting for CD133 and/or CD15. CD133- and/or CD15-
positive GSCs have higher level of pS21 EZH2 compared to
CD133- and/or CD15-negative cells (Figure 6B). Together, these
data show that pS21 EZH2 is preferentially expressed in GSCs
and suggest that pS21 EZH2 is required for the EZH2-STAT3
interaction and STAT3 methylation in GSCs.
EZH2 Phosphorylation at Serine 21 Enhances STAT3
Methylation and Activation
To interrogate the role of pS21 EZH2 in regulating STAT3, we
overexpressed a phosphorylation-defective or phosphorylation
mimetic EZH2 mutant in GSCs and examined the effects on
STAT3 methylation and STAT3 activity (Figures 6C–6G). Expres-
sion of the EZH2 S21A mutant markedly decreased STAT3
methylation similar to a catalytic activity-dead EZH2 H689A
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significantly increased STAT3 methylation (Figures 6C and 6D).
These data prompted us to test whether a low level of STAT3
methylation in U87 glioma cells is due to the low expression of
pS21 EZH2. Exogenous expression of EZH2 S21Dmutant signif-
icantly increased STAT3 methylation and STAT3 activity in U87
cells and NPCs, similar to GSCs (Figure S3 and data not shown).
Furthermore, STAT3 target gene expression (e.g., STAT3 and
SOCS3) and luciferase-based STAT3 transcriptional activity
were significantly high in EZH2 S21D mutant-expressing cells
but low in EZH2 S21A mutant-expressing cells compared to
the control (Figures 6E–6G). Together, these data support the
notion that STAT3 methylation and activation are mediated by
pS21 EZH2.
To interrogate the role of pS21 EZH2 in GSC growth, we over-
expressed various EZH2 constructs in GSCs via lentiviral trans-
duction and determined the effects on clonogenic growth of
GSCs (Figure 6H). Limiting dilution assays were performed and
the frequencies of sphere-forming clonogenic cells were esti-
mated. The frequencies of sphere-forming clonogenic cells
were approximately one out of five cells in the control or wild-
type EZH2 expressing cells. In contrast, most of EZH2 H689A-
expressing cells failed to generate colonies. Ectopic expression
of EZH2 S21A also significantly reduced the number of clono-
genic cells to less than 10% of the controls (Figure 6H).
STAT3 Signaling Is a Crucial Downstream Effector of
EZH2 Signaling in GBM
To interrogate the role of pS21 EZH2, we further analyzed the
effects of EZH2 S21A overexpression in GSCs. Ectopic expres-
sion of a catalytic activity-dead EZH2 H689A mutant in GSCs
decreased methylation of both H3K27 and STAT3 (Figure 3C).
In contrast, expression of EZH2 S21A mutant significantly
decreased STAT3 methylation but increased global levels of
H3K27 trimethylation in GSCs (Figure 7A). Overexpression of
EZH2 S21A mutant in GSCs did not change the level of Dkk1
mRNA expression, suggesting that PRC2-mediated silencing is
unaffected by EZH2 S21A (data not shown). However, EZH2
S21A mutant was unable to immunoprecipitate with STAT3 in
contrast to the wild-type EZH2 (Figure 7B) and pY-STAT3 was
significantly low in EZH2 S21A-expressing cells compared to
the controls (Figure 7A). Because EZH2 S21A mutant-express-
ing cells show the decreased STAT3 activity, we then deter-
mined whether forced activation of STAT3 could rescue the
reduced clonogenic growth in these cells (Figures 7C–7E). We
overexpressed a constitutively active STAT3 mutant (STAT3C)
in EZH2 S21A-expressing GSCs and determined their clono-
genic growth by limiting dilution assays. In the control and
STAT3C-expressing cells, the numbers of clonogenic cells are
similar. Expression of STAT3C in EZH2 S21A mutant cells signif-
icantly increased the number of clonogenic cells (Figure 7E),
suggesting that STAT3 signaling is a crucial downstream effector
of EZH2 signaling in GBM.
To interrogate the role of EZH2 in tumor growth in vivo, we
overexpressed EZH2 H689A or EZH2 S21A proteins in GSCs
and implanted these cells into the brains of SCID mice (50,000
cells per mouse, n = 10 per each group). While animals bearing
control cells died within 2 months (median survival: 47 days),
animals injected with EZH2 H689A-expressing cells survivedsignificantly longer (median survival: 75 days; p < 0.001). Median
survival of the mice bearing EZH2 S21A-expressing cells was
67 days (p < 0.001), which is significantly longer than that of
the controls (Figure 7F). Kaplan-Meier curves showed the in-
crease in survival of mice bearing EZH2 S21A- and EZH2
H689A-expressing tumor (p < 0.001 compared to the control).
These in vivo data demonstrate that the selective blocking of a
STAT3-related arm of EZH2 function can increase the survival
of tumor-bearing mice. Our findings, therefore, support that
EZH2 contributes to GBM tumor growth by both H3K27 trime-
thylation-dependent and STAT3-dependent pathways.
Our data obtained in the models of various patient-derived
GSCs and GBM xenografts in vitro and in vivo suggest that
EZH2 phosphorylation has protumorigenic roles in part via
STAT3 activation. To assess the in vivo relevance of the EZH2-
STAT3 axis, we determined the expression of pS21 EZH2 and
pY-STAT3 in protein lysates from the patient-derived GBM
specimens (Figure S4). The correlation between the expression
of EZH2 and pS21 EZH2 is not always linear; however, there
appears to be a potentially positive correlation between pS21
EZH2 and pY-STAT3 (Figure S4). To determine whether pS21
EZH2 is associated with survival in patients with GBM, we
performed immunohistochemical analysis using the tissue
microarray (TMA) sections containing 87 GBM specimens from
the patients (Figure S4). Expression of pS21 EZH2 displayed in-
ter- and intratumoral heterogeneity. A high frequency of cells
positive for pS21 EZH2 in GBM specimens was positively corre-
lated with the shorter overall survival of the patients (p < 0.001 by
log rank analysis).
Collectively, these data support a model in which EZH2 not
only mediates transcriptional silencing, but also contributes to
the activation of STAT3 signaling in GBM (Figure 7G). We pro-
pose that the molecular mechanism through which EZH2 acti-
vates STAT3 involves a specific EZH2 phosphorylation and
STAT3 methylation.
DISCUSSION
Altered profile of histone modification is a major epigenetic
mechanism, deregulation of which leads to tumor initiation and
propagation (Margueron and Reinberg, 2011; Schlesinger
et al., 2007; Widschwendter et al., 2007). Polycomb-mediated
transcriptional silencing plays a critical role in the maintenance
of the stem cell status in both normal and malignant stem cells.
In this study, we demonstrate that EZH2methylates STAT3 lead-
ing to the enhanced STAT3 activity.
Our data indicate that EZH2 not only mediates transcriptional
silencing, but also contributes to the activation of STAT3
signaling in stem-like GBM cells. As supporting evidence, we
found that the EZH2-STAT3 interaction and EZH2 S21 phos-
phorylation preferentially occur in GSCs relative to non-stem
tumor cells. Overexpression of EZH2 S21D induced STAT3
methylation and enhanced STAT3 activity, suggesting that
EZH2 S21 phosphorylation is a molecular switch that facilitates
STAT3 methylation. We do not know the underlying molecular
mechanism by which the EZH2 S21 phosphorylation is more
prominent in stem-like cells. One possibility is that a cofactor
of PRC2 component preferentially expressed in stem cell popu-
lation (Simon and Kingston, 2009) might facilitate the AKT-EZH2Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc. 847
Figure 7. EZH2 Contributes to GBM Tumor Growth by both H3K27 Trimethylation-Dependent and STAT3-Dependent Pathways
(A and B) Immunoblot and Co-IP analysis of methylated STAT3 and H3K27me3 in GSCs that express GFP, wild-type EZH2, or EZH2 S21A.
(C) Immunoblots of exogenous EZH2 S21A and STAT3-C proteins in 131 GSCs.
(D) Representative images of 131 GSCs expressing EZH2 S21A and STAT3-C protein. Bar represent 50 microns.
(E) Effects of ectopic expression of EZH2 S21A and STAT3-C protein on GSC tumorsphere formation. From limiting dilution assays, frequencies of stem-like
clonogenic cells were calculated using ELDA and presented as a box plot. *p < 0.01.
(F) Kaplan-Meier survival curves of mice (n = 10 for each group) intracranially implanted with 131 GSCs expressing control, EZH2 689A, or EZH2 S21A proteins
(control versus EZH2 H689A, p < 0.0001; control versus EZH2 S21A, p < 0.0001; EZH2 H689A versus EZH2 S21A, p = 0.015 by log rank analysis).
(G) A schematic model that illustrates two functional arms of EZH2. P and Me represent phosphorylation and methylation, respectively.
See also Figure S4.
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possible that EZH2 S21 phosphorylation is regulated by differen-
tial AKT or AKT-related downstream effects which may not
be directly associated with stem-like characteristics. Further848 Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc.studies to decipher underlying molecular mechanisms are war-
ranted as a recent study reported EZH2 S21 phosphorylation
as a critical modification for EZH2 to function as a transcriptional
co-activator with androgen receptor (Xu et al., 2012).
Cancer Cell
EZH2-STAT3 Interaction in Glioblastoma Stem CellsOur data support that EZH2-mediated STAT3 methylation is a
critical modification that leads to STAT3 activation, although the
precise molecular events that link STAT3 methylation to STAT3
activation are unknown. STAT3 activation involves a series of
sequential events including tyrosine phosphorylation, dimeriza-
tion, nuclear import, DNA binding, serine phosphorylation, nu-
clear retention, and binding to protein partners (Akira et al.,
1994; Yang and Stark, 2008; Zhong et al., 1994). It is possible
that K180methylation of STAT3 enhances its tyrosine phosphor-
ylation by protecting it from dephosphorylation, as supported by
K180 STAT3 mutant data. It has been proposed that K140
methylation of STAT3 destabilizes STAT3 tyrosine phosphoryla-
tion, thereby negatively affecting STAT3-dependent transcrip-
tion (Yang et al., 2010). In contrast to K180 STAT3 methylation
by EZH2, K140 methylation can be viewed as a negative event
for STAT3 signaling cascade. By analogy with the cases in P53
and NFkB, specific lysine site and the degree of methylation
will likely determine STAT3 activity. Although K140 methylation
of STAT3 was not detected in our studies, these findings may
suggest a critical role of methylation in STAT3 signaling cascade
in various cancers. In addition to K180 methylation, we also
found K709 dimethylation of STAT3 by MS analysis (data not
shown), suggesting that theremight be additional lysine residues
of STAT3 that could be methylated by EZH2. Further studies are
required to precisely define when lysine methylation of STAT3
occurs during the STAT3 signaling cascade and interrogate the
role of STAT3 methylation in STAT3 activation.
Despite these caveats, there are important biological and clin-
ical implications derived from our findings. First, the EZH2 and
STAT3 signaling pathways are critical therapeutic targets for
GBMs, and our findings suggest that EZH2 targeting may effec-
tively inhibit oncogenic activities of both pathways. Significant
research efforts have been aimed at developing therapeutic
agents targeted for EZH2 because highly specific EZH2 inhibi-
tors have been reported recently (Knutson et al., 2012; McCabe
et al., 2012; Qi et al., 2012). Our findings may lead to accelerated
development of Polycomb/EZH2 targeting agents and provide a
potential biomarker for evaluating therapeutic efficacy.
Second, STAT3 signaling is hyperactive in various cancers
including GBMs and is an important therapeutic target; however,
the specific inactivation of STAT3 has been challenging (Gurya-
nova et al., 2011; Yue and Turkson, 2009). Our finding adds
EZH2 to a growing list of upstream pathways leading to the
STAT3 activation in GSCs, including IL-6, Notch, PI3K, LIF,
BMX, and various receptor tyrosine kinases (epidermal growth
factor receptor, platelet-derived growth factor, and MET) (Brom-
berg et al., 1999; Fan et al., 2010; Guryanova et al., 2011). It will
be highly desirable if EZH2 targeting achieves the effective inhi-
bition of both transcriptional silencing and STAT3 activity in a
clinical setting.
A recent study reported that STAT3 signaling is a master regu-
lator of mesenchymal transformation of gliomas, and that STAT3
downstream genes are highly expressed in the mesenchymal
GBM subtype (Carro et al., 2010; Verhaak et al., 2010). Further
studies aim to identify the subset of tumors in which the EZH2-
STAT3 axis is particularly active, and to demonstrate the mech-
anistic correlations between these pathways. It is enticing to
propose that EZH2 targeting agents may be particularly useful
for patients harboring high levels of phosphorylated EZH2.Inhibition of AKT signaling decreases STAT3 activity via EZH2
phosphorylation, implying that PI3K/AKT signaling is an up-
streammediator of the EZH2-STAT3 interaction in GSCs. Activa-
tion of the PI3K/AKT pathway in glioma is associated with an
adverse clinical outcome and various PI3K/AKT inhibitors are
being tested in clinical trials (Fan et al., 2006; Fan and Weiss,
2010; Cancer Genome Atlas Research Network, 2008; Verhaak
et al., 2010). Our data indicate that EZH2 S21 phosphorylation
is required for the EZH2-STAT3 interaction and the enhanced
STAT3 activity, and AKT inhibition in vivo effectively abolished
pS21 EZH2. Therefore, it would be interesting to examine
pS21 EZH2 expression as a biomarker to predict therapeutic
responses to PI3K/AKT targeted therapies.
In conclusion, we demonstrate that EZH2 binds to and meth-
ylates STAT3, thereby enhancing STAT3 activity in GSCs. EZH2
phosphorylation by AKT is critical for the EZH2-STAT3 interac-
tion. By utilizing EZH2 constructs that allow the dissection of
two distinct functions of EZH2, we showed the role of STAT3-
dependent EZH2 function in GBMs. We propose that two arms
of EZH2 function, namely a histone methylation- dependent
transcriptional silencing and STAT3 activation by direct pro-
tein-protein interaction, can cooperatively contribute to GSC
self-renewal and GBM malignancy. These data suggest that
functional disruption of EZH2 may attenuate multiple key signals
involved in GSC self-renewal and survival, and further support
that EZH2 is a promising therapeutic target for GBM.EXPERIMENTAL PROCEDURES
Human GBM Specimens and Derivative GSCs
Following informed consent, glioblastoma specimens were obtained from
patients undergoing surgery at the Samsung Medical Center in accordance
with the Institutional ReviewBoards.Within hours after surgical removal, tumor
specimens were enzymatically dissociated into single cells, following the pro-
cedures previously reported (Lee et al., 2006a; Son et al., 2009). For short-term
in vitro expansion of GSCs, tumor cells were cultured in Neurobasalmedia with
N2 and B27 supplements (0.53 each; Invitrogen), human recombinant basic
fibroblast growth factor and epidermal growth factor (25 ng/ml each; R&D sys-
tems). HumanNPCswere purchased from Lonza and cultured similar to GSCs.
For differentiation of GSCs and NPCs, cells were cultured in the absence of
growth factors or in the presence of 10% fetal bovine serum (Cellgro).
Intracranial Tumor Cell Injection
All mice experiments were performed according to the guidelines of the Animal
Use and Care Committees at Samsung Medical Center. GBM cells were
dissociated, resuspended in 2 ml of HBSS, and injected intracranially into the
striatum of adult nude mice by using a stereotactic device (Kopf instruments)
(coordinates: 2 mm anterior, 2 mm lateral, 2.5 mm depth from the dura). Mice
with neurologic signs were killed for the analysis of tumor histology and immu-
nohistochemistry. Brains were perfused with 4% paraformaldehyde by car-
diac perfusion and further fixed at 4C overnight.
Chemicals and Antibodies
3-Deazaneplanocin A (DZNep) was kindly provided from Dr. Victor Marquez
(National Cancer Institute). GSK126was purchased from Xcessbio. Cucurbita-
cin and perifosine were purchased from Tocris and Selleckchem, respectively.
The following antibodies were used as primary antibodies: EZH2 (BD Trans-
duction Laboratories; 1:4,000); phospho-EZH2 (Bethyl Laboratories; 1:500);
methylated lysine (Enzo Life Science and Abcam; 1:500); STAT3, phospho-
STAT3 (Y705), histone H3, AKT, and phospho-AKT (S473) (Cell Signaling;
1:2,000); SOX2 and OLIG2 (R&D Systems; 1:2000 for western blotting and
1:400 for IF); trimethylated histone H3K27 and SUZ12 (Millipore; 1:1,000);
GFAP (Dako; 1:1,000); b-actin (Sigma-Aldrich; 1:5,000).Cancer Cell 23, 839–852, June 10, 2013 ª2013 Elsevier Inc. 849
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Cells were collected and lysed in lysis buffer supplemented with protease
inhibitors, incubated on ice for 15 min, and cleared by centrifugation at
13,200 rpm at 4C for 15 min. Total protein lysate (500 mg) was subjected to
immunoprecipitation with the agarose-immobilized antibody (1 mg of anti-
STAT3, EZH2, methylated lysine antibody, or isotype control antibodies) for
overnight at 4C.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.04.008.
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